CentraCare Health

DigitalCommons@CentraCare Health
Articles

Posters and Scholarly Works

2017

Ambulatory Hemodynamic Monitoring Reduces
Heart Failure Hospitalizations in "Real-World"
Clinical Practice
Akshay S. Desai
Brigham and Women's Hospital, Boston MA

Arvind Bhimaraj
Houston Methodist Hospital, Houston TX

Rita Jermyn
Abbot, Sylmar CA

Jamie M. Pelzel
St. Cloud Hospital, CentraCare Health, pelzelj@centracare.com

Follow this and additional works at: https://digitalcommons.centracare.com/articles
Part of the Cardiology Commons
Recommended Citation
Desai, Akshay S.; Bhimaraj, Arvind; Jermyn, Rita; and Pelzel, Jamie M., "Ambulatory Hemodynamic Monitoring Reduces Heart
Failure Hospitalizations in "Real-World" Clinical Practice" (2017). Articles. 82.
https://digitalcommons.centracare.com/articles/82

This Article is brought to you for free and open access by the Posters and Scholarly Works at DigitalCommons@CentraCare Health. It has been
accepted for inclusion in Articles by an authorized administrator of DigitalCommons@CentraCare Health. For more information, please contact
schlepers@centracare.com.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

VOL. 69, NO. 19, 2017

ª 2017 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER

ISSN 0735-1097/$36.00
http://dx.doi.org/10.1016/j.jacc.2017.03.009

ORIGINAL INVESTIGATIONS

Ambulatory Hemodynamic Monitoring
Reduces Heart Failure Hospitalizations in
“Real-World” Clinical Practice
Akshay S. Desai, MD, MPH,a Arvind Bhimaraj, MD, MPH,b Rupinder Bharmi, MS,c Rita Jermyn, MD,d
Kunjan Bhatt, MD,e David Shavelle, MD,f Margaret M. Redﬁeld, MD,g Robert Hull, MD,h Jamie Pelzel, MD,i
Kevin Davis, BS,c Nirav Dalal, MS, MBA,c Philip B. Adamson, MD,c J. Thomas Heywood, MDj

ABSTRACT
BACKGROUND In the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New
York Heart Association [NYHA] Functional Class III Heart Failure Patients) trial, heart failure hospitalization (HFH) rates were
lower in patients managed with guidance from an implantable pulmonary artery pressure sensor compared with usual care.
OBJECTIVES This study examined the effectiveness of ambulatory hemodynamic monitoring in reducing HFH outside
of the clinical trial setting.
METHODS We conducted a retrospective cohort study using U.S. Medicare claims data from patients undergoing
pulmonary artery pressure sensor implantation between June 1, 2014, and December 31, 2015. Rates of HFH during
pre-deﬁned periods before and after implantation were compared using the Andersen-Gill extension to the Cox
proportional hazards model while accounting for the competing risk of death, ventricular assist device implantation,
or cardiac transplantation. Comprehensive heart failure (HF)–related costs were compared over the same periods.
RESULTS Among 1,114 patients receiving implants, there were 1,020 HFHs in the 6 months before, compared with
381 HFHs, 139 deaths, and 17 ventricular assist device implantations and/or transplants in the 6 months after implantation
(hazard ratio [HR]: 0.55; 95% conﬁdence interval [CI]: 0.49 to 0.61; p < 0.001). This lower rate of HFH was associated with
a 6-month comprehensive HF cost reduction of $7,433 per patient (IQR: $7,000 to $7,884), and was robust in analyses
restricted to 6-month survivors. Similar reductions in HFH and costs were noted in the subset of 480 patients with complete
data available for 12 months before and after implantation (HR: 0.66; 95% CI: 0.57 to 0.76; p < 0.001).
CONCLUSIONS As in clinical trials, use of ambulatory hemodynamic monitoring in clinical practice is associated with
lower HFH and comprehensive HF costs. These beneﬁts are sustained to 1 year and support the “real-world” effectiveness of this approach to HF management. (J Am Coll Cardiol 2017;69:2357–65) © 2017 by the American College of
Cardiology Foundation.
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ABBREVIATIONS

D

espite considerable progress in the

represent real-world effectiveness during general

development of effective medical

use in clinical practice. The early experience of

therapy,

chronic

hemodynamic-guided HF management does suggest

heart failure (HF) remain at high risk for

that the PAP reductions achieved with hemodynamic

recurrent hospitalization and death (1). In

monitoring in the “real world” are comparable to those

the Medicare-eligible population, roughly

observed during the CHAMPION trial (17). It remains

1 in 4 patients are readmitted within 30

unclear, however, whether these pressure reductions

days of hospitalization, and nearly one-half

have meaningfully inﬂuenced the rate of HFH in

pressure

are readmitted within 6 months (2). Most of

implanted patients. We examined publicly available

VAD = ventricular assist device

these hospitalizations are related to conges-

administrative claims data from the U.S. Centers for

tive exacerbations driven by a progressive

Medicare & Medicaid Services (CMS) to compare the

rise in intracardiac ﬁlling pressures, independent of

rates of HFH and the costs associated with HF care in

ejection fraction or etiology (3–7).

the periods before and after PAP sensor implantation.

AND ACRONYMS
CMS = Centers for Medicare
and Medicaid Services

HF = heart failure
HFH = heart failure
hospitalization

PAP = pulmonary artery

patients

with

SEE PAGE 2366

METHODS

Data from trials of implantable hemodynamic
monitoring demonstrate that in many (although not all)

DATA

cases, ﬁlling pressures rise weeks in advance of symp-

COHORT. We conducted a retrospective cohort study

toms sufﬁcient to trigger clinical attention, suggesting a

using CMS administrative claims data from the Stan-

window of opportunity to intervene to prevent heart

dard Analytic File to evaluate health care utilization in

failure hospitalizations (HFHs) with early detection of

U.S. fee-for-service Medicare beneﬁciaries receiving a

congestion (8). Although several methods for remote

PAP sensor implant during the period following FDA

monitoring of HF patients have been considered, ap-

approval for commercial use (from June 1, 2014, on-

proaches that focus on weight (9–11) and changes in

ward). These data include Part A inpatient claims, Part

device-based

B outpatient claims, and the associated denominator

diagnostics

(such

as

intrathoracic

SOURCE

AND

IDENTIFICATION

OF

THE

impedance [12]) have not been effective in reducing

ﬁles (18). The inpatient and outpatient ﬁles contain

hospitalization rates. In contrast, HF management

institutional claims with International Classiﬁcation

guided by longitudinal access to pulmonary artery

of Diseases-Ninth or -Tenth Revision-Clinical Modiﬁ-

pressures (PAPs) was associated with substantial

cation diagnosis codes, procedure codes, and reim-

reduction in rates of HFH in the CHAMPION (Car-

bursement

dioMEMS Heart Sensor Allows Monitoring of Pressure

ambulatory visits. The denominator ﬁles include

associated

with

inpatient

stays

or

to Improve Outcomes in New York Heart Association

unique deidentiﬁed patient identiﬁcations, age, sex,

[NYHA] functional Class III Heart Failure Patients) trial.

geographic location, race or ethnicity, date of death (if

These beneﬁts persisted over the full duration of ran-

present), and information about program eligibility

domized follow-up (13), were consistent in patients

and Medicare insurance enrollment.

with both preserved and reduced ejection fraction (14)

PAP sensor implants were identiﬁed by inpatient

as well as Medicare-eligible subjects (15), and were

claims associated with the procedure codes 38.26,

tightly linked to the achieved reduction in PAP with

02HQ30Z, or 02HR30Z and outpatient claims associ-

diuretic agents and other guideline-directed pharma-

ated with Current Procedural Terminology codes

cological therapies (16). Based on these observations, in

C9741 and C2624 (Online Table 1). As Medicare data

May 2014, the U.S. Food and Drug Administration (FDA)

were available through June 30, 2016, only implants on

approved the CardioMEMS HF System (Abbott, Sylmar,

or before December 31, 2015, were included to ensure a

California) as an approach to reducing HFH in patients

minimum of 6 months of potential follow-up. The

with chronic HF, New York Heart Association functional

cohort was further limited to patients with contin-

class III functional capacity, and a hospitalization for

uous, fee-for-service (non–health maintenance orga-

HF management in the year prior to implantation.

nization) Medicare insurance enrollment (Parts A and

Therapeutic efﬁcacy of an intervention in select

B) for at least 6 months before and after implantation,

populations managed within the tightly regulated

retaining those who died at any time post-implant

framework of a clinical trial may not accurately

(6-month cohort). A subset of patients who received

Dr. Heywood has received honorarium, served as a consultant, and received research and fellowship support from St. Jude
Medical (now Abbott). Dr. Hull has reported that he has no relationships relevant to the contents of this paper to disclose.
Manuscript received February 18, 2017; revised manuscript received March 2, 2017, accepted March 3, 2017.
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implants before June 30, 2015, with continuous

post-implant period. Classiﬁcation of an encounter as

Medicare enrollment and follow-up data available for

being HF-related or not was made on the basis of the

12 months before and after device implantation were

presence of an HF code (Online Table 2) in the primary

considered in a separate analysis (12-month cohort).

diagnosis code position, as per the published CMS

The analysis plan was jointly conceived by the prin-

methodology (19). The principal cost comparison was

cipal author (A.S.D.) in partnership with the sponsor,

between the 6 months before and after implantation,

with all statistical analyses performed by the out-

but analyses were repeated for the cohort of patients

comes research group (R.B., K.D., and N.D.) at Abbott

with 12-month (pre/post) data available. A nonpara-

(Sylmar, California). The claims data were extracted

metric bootstrap method (21,22) was used for comparing

using Apache Spark version 2.0.1 (Apache Software

the pre- and post-implant costs (Online Appendix).

Foundation, Forest Hill, Maryland) with Python

SENSITIVITY AND SUBGROUP ANALYSES. Because some

version 3.5.2 (Python Software Foundation, Beaver-

implants occurred in the midst of an HF hospitalization,

ton, Oregon), and the statistical analyses were con-

sensitivity analyses restricted to outpatient implants

ducted using Revolution R version 3.1.1. (Revolution

were performed to assess consistency of the results. To

Analytics, Mountain View, California). An indepen-

further address possible confounding of the analyses by

dent review of the results was conducted by external

the competing risk of death, we repeated analyses in

health care economic consultants before publication.

cohorts restricted to patients who survived the full

The paper was drafted by the principal author (A.S.D.),

analytic interval (6 or 12 months). Results in subgroups

with input from all coauthors.

deﬁned by sex and age $75 years were also analyzed

ANALYSIS OF EFFECTIVENESS. We compared rates

due to concerns previously raised regarding differential

of HFH (deﬁned using the published CMS methodol-

efﬁcacy of hemodynamic monitoring in these groups.

ogy [19]) and all-cause hospitalization during the

Additional sensitivity analyses, consisting of general-

6 months before and following device implantation

ized estimating equations (GEE) models using both

using the Andersen-Gill model for recurrent events,

Poisson and negative binomial models, further sup-

with censoring at the time of death, ventricular
assist device (VAD) implantation, or cardiac transplantation. For the subset of patients with available
data, we separately analyzed the same hospitalization
rates during the 12 months before and following device
implantation. Heart transplant or VAD implantation
was identiﬁed using a Medicare severity diagnosis
related groups assignment of 001 or 002 (heart transplant or implant of heart assist system without major
comorbidity or complication). For all analyses, event
accumulation was analyzed forward and backward
from the date of PAP sensor implant. A robust variance
estimate (20) was used in the Andersen-Gill model to
account for possible within-participant dependence.

ported the ﬁndings.

RESULTS
Of 1,935 Medicare patients who underwent a PAP
sensor implantation from June 1, 2014, to December 31,
2015, there were 1,114 who were continuously enrolled
and had available data regarding health care utilization for at least 6 months before and after implantation, and 480 who had complete data for 12 months
before and after implantation (see Figure 1 for details
of patient selection). For the 6-month cohort, the majority of PAP sensor implants (n ¼ 832; 74.7%) occurred
in the ambulatory setting, rather than during an HF
hospitalization. Among patients who underwent PAP

ANALYSIS OF COSTS. As HFH is a principal driver of

sensor implantation in the outpatient setting, the

health care costs, we simultaneously conducted a

average time from the most recent HFH to device im-

comparison of the comprehensive (inpatient and

plantation was 63.2  47.5 days. Selected patient

outpatient) costs associated with HF care during the

characteristics at the time of sensor implantation for

periods before and after implantation. For patients

the 6- and 12-month cohorts are summarized in Table 1.

implanted in an outpatient setting, the health care

Overall, for both cohorts, the mean age was 71  11

encounter containing the relevant Current Procedural

years, with 40% of subjects at least 75 years of age, 36%

Terminology

implant

women, 14% black race, and a large burden of comor-

encounter, with events before and after this encounter

bid medical illness, including diabetes, hypertension,

attributed to the pre- and post-implant periods,

and chronic obstructive pulmonary disease.

code

was

deﬁned

as

the

respectively. For patients who had a PAP sensor

Clinical outcomes for the 6 months before and after

implanted in an inpatient setting, the associated hos-

implantation are summarized in Table 2. For the

pitalization and any preceding events were counted

entire cohort, there were 1,899 all-cause hospitaliza-

toward the pre-implant period, whereas any encounters

tions and 1,020 HFHs in the 6 months before

after hospital discharge were counted toward the

implantation,

compared

with

1,119

all-cause
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T A B L E 1 Patient Characteristics (on the Basis of Medicare Claims

F I G U R E 1 Flow Diagram of Patient Selection

Data) at the Time of PAP Sensor Implantation for Cohorts With
6- and 12-Month Data Available

1,935 patients with PAP
sensor implants from
June 1, 2014-June 30, 2016

694 implanted after Jan 1, 2016

6-Month Cohort
(n ¼ 1,114)

12-Month Cohort
(n ¼ 480)

Age, yrs

71.3  10.8

71.4  11.4

Age $75 yrs

460 (41.3)

211 (44.0)

Female

403 (36.2)

180 (37.5)

White

902 (81.0)

396 (82.5)

Black

161 (14.5)

69 (14.4)

Other

51 (4.6)

15 (3.1)

727 (65.3)

311 (64.8)

Race

1,241 with minimum 6-month
follow-up data available

Comorbidities*
Diabetes

127 not continuously enrolled
in Medicare Part A and B or
enrolled in HMO insurance

Hypertension
COPD

1,089 (97.8)

471 (98.1)

861 (77.3)

384 (80.0)

Values are mean  SD or n (%). *Comorbidities identiﬁed using diagnosis codes
from health care encounters in the 6 months before implant.
COPD ¼ chronic obstructive pulmonary disease; PAP ¼ pulmonary artery pressure.

1114
6-month cohort (Primary analysis)

conﬁdence interval [CI]: 0.49 to 0.61; p < 0.001).
556 implanted after June 30, 2015

This

observation

was

consistent

in

analyses

restricted to 6-month survivors (excluding those with
post-implant death, VAD, or transplant), in subgroups
deﬁned by sex and age $75 years, across all Medicare

558 with minimum 12-month
follow-up data available

administrative contractors, and in analyses restricted
to outpatient implants (Figure 2, Online Figure 1).
78 not continuously enrolled
in Medicare Part A and B; or
enrolled into HMO insurance

Additional sensitivity analyses using both a Poisson
GEE model and negative binomial regression GEE
model were performed, which further supported the
robustness of the results. For the Poisson model, the

480
1 year cohort (Secondary analysis)

incidence rate ratio was 0.60 (95% CI: 0.53 to 0.68),
and for the negative binomial regression models it
was 0.64 (95% CI: 0.57 to 0.73).
Reductions in HFH were associated with an esti-

Shown are the criteria used to select the 6- and 12-month cohorts for analysis from the
total number of identiﬁed PAP sensor implants in the Medicare cohort during the period
from June 1, 2014 to June 30, 2016. HMO ¼ health maintenance organization;
PAP ¼ pulmonary artery pressure.

mated reduction in costs related to HF care of $7,433/
patient in the 6 months following implantation relative to the period before implantation (IQR: $7,000
to $7,884/patient at 6 months before implantation;
p < 0.001). All-cause hospitalizations were also

hospitalizations, 381 HFHs, 17 VAD implantations or

reduced in the post-implant interval (HR: 0.69; 95%

transplants, and 139 deaths in the 6 months after

CI: 0.64 to 0.75; p < 0.001), with associated reduction

device implantation. A total of 81% of patients were

in total health care costs (Table 2).

hospitalized at least once for any cause in the

Clinical outcomes for the subset of patients with

6 months before device implantation, compared with

complete 12-month data available for the period

50% of patients in the 6 months after implant.

before and after implantation are summarized in

Further, 59% of patients had at least 1 HFH pre-

Table 2. For these 480 subjects, there were 1,387

implant, compared with 22% of patients during the

all-cause hospitalizations and 696 HFHs in the

6 months post-implant. The median number of HFHs

12 months before implantation, compared with 859

per patient was 0.92 at 6 months before and 0.37 at 6

all-cause

months after device implantation. As shown in the

implantations or transplants, and 106 deaths after

Central Illustration, Panel A, the cumulative incidence

device implantation. As observed at 6 months, rela-

of HFH was signiﬁcantly lower in the period following

tive to the pre-implant interval, the cumulative

device implantation (hazard ratio [HR]: 0.55; 95%

incidence of HFH was also signiﬁcantly lower in the

hospitalizations,

300
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T A B L E 2 Clinical Outcomes and Health Care Costs Before and After PAP Sensor Implantation for the 6- and 12-Month Cohorts

6-Month Cohort
(n ¼ 1,114)

Follow-up, patient-yrs
All-cause hospitalizations
HF-related
Non–HF-related
Days alive and out of hospital, %

12-Month Cohort
(n ¼ 480)

Pre-Implant

Post-Implant

Pre-Implant

557

513

480

Post-Implant

413

1,899

1,119

1,387

859

1,020

381

696

300

879

738

691

559

93.9%

95.6%

94.8%

95.7%

VAD/Transplant

0

17

0

15

Deaths

0

139

0

106

Costs*
HF-related

$12,410
($12,050 to $12,800)

D cost (post  pre)

$4,945
($4,633 to $5,300)

$7,433 ($7,000 to $7,884)

All-cause

$28,870
($28,240 to $29,440)

D cost (post  pre)

$18,360
($17,710 to $18,970)

$10,510 ($9,703 to $11,330)

$19,900
($19,210 to $20,720)

$8,690
($8,057 to $9,291)

$11,260 ($10,460 to $12,020)
$47,690
($46,370 to $48,910)

$34,500
($33,110 to $36,000)

$13,190 ($11,590 to $14,740)

Values are n unless otherwise indicated. *Costs shown are per-patient/6 months for the 6-month cohort and per patient-yr for the 12-month cohort, along with IQR
(in parenthesis).

D ¼ change; HF ¼ heart failure; PAP ¼ pulmonary artery pressure; VAD ¼ ventricular assist device.

implantation

utilization in the post-implant period translated into

(HR: 0.66; 95% CI: 0.57 to 0.76; p < 0.001) (Central

substantial cost reductions at both 6 months and at

Illustration, Panel B). Observed reductions in compre-

1 year compared with the pre-implant interval. These

hensive HF costs relative to the pre-implant period

data, which are robust in competing risk models and in

were estimated at $11,260 per patient-year (IQR:

sensitivity analyses restricted to survivors as well as

12-month

period

following

device

$10,460 to $12,020 per patient-year; p < 0.001).

ambulatory implants, provide “real-world evidence”

The reduction in all-cause hospitalization was also

in an unselected population supporting the incre-

sustained at 12 months (HR: 0.77; 95% CI: 0.70 to 0.86;

mental value of this approach to HF management.

p < 0.001), as were the reductions in total costs
compared with the pre-implant interval (Table 2).

Although randomized clinical trials remain the gold
standard for regulatory approval, regulatory agencies
have increasingly acknowledged that real-world data

DISCUSSION

may be used to generate valid scientiﬁc evidence
regarding device safety and effectiveness in a wider

This analysis of publicly available data reﬂecting

patient population than that enrolled in a traditional

clinical utilization of implantable hemodynamic

clinical trial (23). Accordingly, FDA approval of the PAP

monitoring in Medicare patients during the commer-

sensor system was linked to the requirement to

cial period post-FDA approval suggest that the

conduct a formal post-marketing study to demonstrate

reductions in HFH and cost savings seen in trial pop-

that the results achieved in the CHAMPION trial could

ulations may also be achievable in clinical practice.

be replicated during commercial use. Pending the re-

The 45% lower rate of cumulative HFH observed at 6

sults of the post-approval study (NCT02279888), these

months after PAP sensor implant versus the 6 months

retrospective data from the Medicare population pro-

prior to implantation compares favorably with the 28%

vide supportive data suggesting that the beneﬁts of

reduction seen with PAP-guided therapy over the same

ambulatory hemodynamic monitoring seen in clinical

time period in the randomized CHAMPION study that

trials may be generalizable to a broader clinical context

supported the initial FDA approval. Moreover, the

(24). Important caveats to this analysis include the

smaller cohort with 1-year pre- and post-implant data

absence of Part D Medicare claims data, which pre-

suggest that, as in the trial, these beneﬁts may be du-

cludes a detailed analysis of medication changes

rable over longer-term follow-up, with a 34% reduc-

following device implantation, as well as the lack of

tion in HFH sustained at 12 months. Concomitant

linked PAP sensor data, which makes it challenging to

reductions

hospitalization

conﬁrm that physicians intervened to treat elevated

following device implantation suggest that reduced

PAPs. Accordingly, we are unable to deﬁnitively

HFHs were not balanced by an increase in non–HF-

ascertain whether reduced HFH rates are related to

related events. Overall reductions in health care

undertreatment in the pre-implant period or improved

observed

in

all-cause

Downloaded for Anonymous User (n/a) at CentraCare Health from ClinicalKey.com by Elsevier on October 30, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.

2361

2362

Desai et al.

JACC VOL. 69, NO. 19, 2017
MAY 16, 2017:2357–65

HFH Reductions With PAP Monitoring

C E NT R AL IL L U STR AT IO N Cumulative HFHs During the Period Before and After Pulmonary Artery Pressure
Sensor Implantation

A

B
700
HR 0.55, 95% CI
(0.49-0.61)
p<0.001

800

Cumulative HF Hospitalizations

Cumulative HF Hospitalizations

1000

600

400

200

600

HR 0.66, 95% CI
(0.57-0.76)
p<0.001

500
400
300
200
100
0

0
Pre-implant: 0
Post-implant: 0

-1mo -2mo -3mo -4mo -5mo -6mo
1mo 2mo 3mo 4mo 5mo 6mo

Number at risk

Pre-implant: 0
Post-implant: 0

-2mo -4mo -6mo -8mo -10mo -12mo
2mo 4mo 6mo 8mo 10mo 12mo

Number at risk

Pre-implant

1114

1114

1114

1114

1114

1114

1114

Pre-implant

480

480

480

480

480

480

480

Post-implant

1114

1080 1049

1019

1002

976

955

Post-implant

480

450

435

409

394

373

357

Pre-implant HFH

Post-implant HFH

Desai, A.S. et al. J Am Coll Cardiol. 2017;69(19):2357–65.

(A) 6-month cohort. (B) 12-month cohort. Hazard ratios were derived using the Andersen-Gill extension of the Cox proportional hazards model, accounting for the
competing risk of death, ventricular assist device, or transplant. Note that event accumulation during the pre-implant interval is counted backward from the time of
implant. Data highlight signiﬁcant reductions in cumulative HFHs in the period after device implantation compared with the period before implantation for both the
6- and 12-month cohorts. CI ¼ conﬁdence interval; HF ¼ heart failure; HFH ¼ heart failure hospitalization; HR ¼ hazard ratio.

treatment in the post-implant period. Related data

cohort sampled for this study is nearly 4 the size of

from the ﬁrst 2,000 commercial PAP sensor implants

the CHAMPION trial treatment arm, and includes a

(including both Medicare and non-Medicare patients)

larger proportion of women (40% vs. 23%) and elderly

do suggest that PA pressure reductions achieved in

subjects (mean age 71 years vs. 61 years; 40% over

clinical practice are even greater than those seen in the

75 years of age). Data from this broader patient sam-

pivotal CHAMPION trial (17), and changes in PAP appear

ple reinforce the CHAMPION results by highlighting a

to be tightly linked to clinical outcomes (25). Overall,

numerically greater reduction in HF hospitalizations

therefore, it seems reasonable to infer that the reduc-

at 6 months than that seen in the trial, and provide

tion in HFH is, in at least some measure, related to ac-

reassurance that these beneﬁts are consistent across

tion taken by clinicians in response to PAP sensor data.

key subgroups of interest.

Despite FDA approval, there has been an ongoing

Although this is not a formal cost-effectiveness

dispute regarding the efﬁcacy of hemodynamic

analysis, these data regarding device utilization in

monitoring, principally due to concerns regarding the

the commercial setting do provide some important

design of the pivotal trial (26). As well, during the

assurances regarding the economic implications of

initial FDA review of the CHAMPION data, concerns

ambulatory hemodynamic monitoring. First, observed

were raised about a possible variation in the beneﬁt of

rates of device utilization in the Medicare population

hemodynamic

as

are far lower than those that drove early projections of

women in the treatment arm had a numerically

the potentially large budgetary effect of device

greater (but statistically nonsigniﬁcant) rate of HFH

approval (28). Second, the observed reduction in

than those in the control arm (27). The Medicare

hospitalizations following device implantation is

monitoring

according

to

sex,
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F I G U R E 2 HFHs in Subgroups of Interest During Period Before and After PAP Sensor Implant (6-Month Cohort)

Subgroup

n

Hazard Ratio for HFH
(post- vs pre-implant)

Age
< 75yrs

654

0.57 [0.49 – 0.66]

≥ 75yrs

460

0.50 [0.42 – 0.60]

Male

711

0.53 [0.45 – 0.61]

Female

403

0.58 [0.48 – 0.69]

Outpatient

832

0.50 [0.44 – 0.58]

Any

1114

0.55 [0.49 – 0.61]

Excluding Deaths

975

0.36 [0.31 – 0.42]

Excluding Death/VAD/Transplant

958

0.36 [0.31 – 0.42]

Sex

Type of Implant

0.0

0.2

0.4

0.6

0.8

1.0

1.2

Hazard Ratio for HFH (post- vs pre-implant)

Results for each subgroup reported as hazard ratios with 95% conﬁdence intervals, adjusted for competing risk of death, VAD, or
transplantation. These data demonstrate consistent reductions in HFHs in subgroups deﬁned by age and sex, as well as in cohorts excluding
post-implant deaths as well as post-implant death/VAD/transplant (to address potential survivor bias). HFH ¼ heart failure hospitalization;
PAP ¼ pulmonary artery pressure; VAD ¼ ventricular assist device.

numerically higher than that seen in the trial, sup-

for the personnel costs associated with remote

porting even greater cost reductions during the post-

management. As this was a cohort-based comparison

implant interval than projected from the CHAMPION

of outcomes before and after device implantation, not

data alone. Finally, the observation of sustained HFH

a prospective randomized study, we cannot exclude

and cost reductions out to 1 year in a real-world pop-

the possibility that selection bias or enhancements of

ulation supports the notion that the beneﬁts of

HF disease management in the period after device

hemodynamic monitoring may be durable over longer-

implant may also have confounded our results. How-

term follow-up, a factor that is essential for long-term

ever, because all patients had previously been hospi-

cost-effectiveness. Based on an average Medicare

talized for HF, and because all implanting centers were

reimbursement of $23,122  $16,891 for device

selected for their experience in HF management, it is

implantation in this cohort, the reduction of $13,190/

likely that background medical therapy did not differ

patient in comprehensive health care costs among

markedly in the periods before and after implantation.

survivors over 1 year suggests a break-even point of

Moreover, because HF is a progressive disease, with

roughly 2 years to recoup the initial investment.

rates of hospitalization accelerating with progression

STUDY

these analyses were

conservative estimate of the reductions in worsening

derived from Medicare claims data, and accordingly

HF, health care utilization, and cost that are likely to

we are unable to provide details regarding medical

be seen with ambulatory hemodynamic monitoring in

history, ejection fraction, the indication for PAP sensor

practice. Although censoring at the time of death,

implantation, quality of life, device safety, and the

VAD, and transplant introduces the potential for sur-

like. An objective method of identifying HFH per CMS

vivor bias, consistent reductions in HFH in models

methodology was used for this claims dataset, and

accounting for competing risks, as well as sensitivity

there was no formal clinical event adjudication. Only

analyses restricted to patients at risk for the full

Medicare charges were incorporated in the cost

duration of follow-up (6 or 12 months), suggest that

analyses, and accordingly, we are unable to account

this bias did not meaningfully inﬂuence the results.

toward the end stage, these results likely reﬂect a
LIMITATIONS. First,
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CONCLUSIONS

PERSPECTIVES

These data from the “real-world” experience of
Medicare implants of PAP sensors during the period
following device approval suggest that the use of

COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Use of an implantable PAP

ambulatory hemodynamic monitoring is associated

sensor to guide HF management in Medicare patients

with reductions in HFH and overall costs associated

managed in clinical practice is associated with reduc-

with HF care. In tandem with data suggesting
effective reductions in PAPs among general-use pa-

tions in HFHs and all-cause hospitalizations comparable
to the rates reported in clinical trials. This suggests

tients who had the PAP sensor system implanted

that, for eligible patients, the addition of ambulatory

since FDA approval (17), these observations support

hemodynamic monitoring to standard HF care may

the generalizability of the CHAMPION trial results to

reduce resource utilization and health care costs.

clinical practice and argue for clinical effectiveness
of ambulatory hemodynamic monitoring as a strategy for HF management.
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